From: The clinical use of biomarkers as prognostic factors in Ewing sarcoma
Author | Year | Biomarker | Pt number | P |
---|---|---|---|---|
Craft et al, Eur J Cancer 33 (7), 1061-9[8] | 1997 | LDH | 142 | NS |
Aparicio et al, Oncology 55, 20-6[9] | 1998 | LDH | 116 | 0.001 |
Givens et al, Int J Oncol 14 (6), 1039-43[12] | 1999 | LDH | 85 | NS |
Bacci et al, Oncol Rep 6 (4), 807-11[71] | 1999 | LDH | 618 | S |
Luksch et al, Tumori 85 (2), 101-7[41] | 1999 | LDH | 73 | S |
Bacci et al, J Clin Oncol 18, 4-11[13] | 2000 | LDH | 359 | 0.0003 |
Matsunobu et al, Clin Cancer Res 10, 1003-12[29] | 2004 | LDH | 21 | NS |
Bacci et al, Acta Oncol 45, 469-75[16] | 2006 | LDH | 579 | 0.0005 |
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] | 2007 | LDH | 28 | 0.99 |
Yabe et al, Oncol Rep 19 (1), 129-34[70] | 2008 | LDH | 20 | NS |
Leavey et al, Pediatr Blood Cancer 51 (3), 334-8[18] | 2008 | LDH | 262 | 0.0016 |
Xie et al, Chin J Cancer 29 (4), 420-4 | 2010 | LDH | 18 | NS |
Terrier et al, Eur J Cancer 31 (3), 307-14[36] | 1995 | Filigree pattern | 315 | 0.044 |
Terrier et al, Eur J Cancer 31 (3), 307-14[36] | 1995 | Dark cells | 315 | 0.043 |
Aparicio et al, Oncology 55, 20-6[9] | 1998 | Albumine levels | 116 | 0.0006 |
Sollazzo et al, Tumori 85 (3), 167-73[56] | 1999 | c-myc | 38 | S |
Ohali et al, Oncogene 23, 8997-9006[60] | 2004 | MTA1 | 20 | 0.003 |
Cheung et al, Clin Cancer Res 13 (23), 6978-83[32] | 2007 | NKX2-2 | 28 | 0.0017 |
Kikuta et al, Clin Cancer Res 15 (8), 2885-94[20] | 2009 | Nucleophosmin positivity | 8 | 0.01 |
Meynet et al, Cancer Res 70 (9), 3730-8[55] | 2010 | Xg expression | 97 | 0.047 |